How the pharmaceutical industry can support vitality for both human and planetary health in 2024

In response to the heightened demand for transparency and environmental stewardship, especially from health authorities in the pharmaceutical sector, industry players are undergoing a transformative shift toward integrating planet health with human health. Quantis experts have identified three pivotal pillars for 2024 that will play a critical role in shaping the future of sustainable pharmaceutical companies.  

1. Increase ecodesign & circularity. 

Ecodesign is essential to address the rising demand from health authorities and regulators for increased transparency around the environmental impacts of pharmaceutical products. This approach not only allows organizations to align with stakeholder expectations but also fosters a culture of accountability within the industry, accelerating the shift towards sustainable and responsible manufacturing practices. 

2. Adopt sustainable manufacturing & supply chain practices. 

The market is increasingly demanding more sustainable manufacturing processes, waste reduction, and the integration of sustainable practices within the supply chain. When implemented correctly, these changes increase process efficiency, enhance product quality and ensure long-term business continuity and resilience.  

3. Set an integrated nature strategy and science-based targets. 

Given the functional integrity of ecosystems is critical for human health, it’s imperative that pharma companies assess their nature-related risks, set science-based targets for nature and develop a detailed action plan to preserve their ability to develop new drugs and medicines. This shift in focus acknowledges the interconnectedness of pharmaceutical activities with nature, aligning the sector with broader environmental objectives and enacting sustainable transformation within the industry.